L
Lars Wallentin
Researcher at Uppsala University Hospital
Publications - 72
Citations - 4263
Lars Wallentin is an academic researcher from Uppsala University Hospital. The author has contributed to research in topics: Myocardial infarction & Acute coronary syndrome. The author has an hindex of 31, co-authored 72 publications receiving 3931 citations. Previous affiliations of Lars Wallentin include Hochschule Hannover & University of Sheffield.
Papers
More filters
Journal ArticleDOI
Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis
Philippe Steg,Stefan James,Robert A. Harrington,Diego Ardissino,Richard C. Becker,Christopher P. Cannon,Håkan Emanuelsson,Ariel Finkelstein,Steen Husted,Hugo Katus,Jan Kilhamn,Sylvia Olofsson,Robert F. Storey,W. Douglas Weaver,Lars Wallentin +14 more
TL;DR: Ticagrelor, a reversible oral P2Y12-receptor antagonist, provides faster, greater, and more consistent platelet inhibition than clopidogrel and may be useful for patients with acute ST-segment elevation (STE) ACS and planned primary percutaneous coronary intervention as discussed by the authors.
Journal ArticleDOI
Influence of Renal Function on the Effects of Early Revascularization in Non-ST-Elevation Myocardial Infarction Data From the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)
Karolina Szummer,Pia Lundman,Stefan H. Jacobson,Staffan Schon,Johan Lindbäck,Ulf Stenestrand,Lars Wallentin,Tomas Jernberg,for Swedeheart +8 more
TL;DR: Early invasive therapy is associated with greater 1-year survival in patients with non–ST-elevation myocardial infarction and mild-to-moderate renal insufficiency, but the benefit declines with lower renal function, and is less certain in those with renal failure or on dialysis.
Journal ArticleDOI
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
Anna Norhammar,Klas Malmberg,Erik Diderholm,Bo Lagerqvist,Bertil Lindahl,Lars Rydén,Lars Wallentin +6 more
TL;DR: Factors beyond the extent of flow-limiting coronary lesions are of considerable importance for outcome in diabetic subjects with unstable coronary syndromes.
Journal ArticleDOI
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Shamir R. Mehta,Christopher B. Granger,John W. Eikelboom,Jean-Pierre Bassand,Lars Wallentin,David P. Faxon,Ron J.G. Peters,Andrzej Budaj,Rizwan Afzal,Susan Chrolavicius,Keith A.A. Fox,Salim Yusuf +11 more
TL;DR: The use of standard UFH in place of fondaparinux at the time of PCI seems to prevent angiographic complications, including catheter thrombus, without compromising the benefits of upstream fondAParinux.
Journal ArticleDOI
Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction
Tibor Kempf,Erik Björklund,Sylvia Olofsson,Bertil Lindahl,Tim Allhoff,Timo Peter,Jörn Tongers,Kai C. Wollert,Lars Wallentin +8 more
TL;DR: GDF-15 provided prognostic information in clinically relevant patient subgroups, defined according to age, gender, cardiovascular risk factors, haemodynamic status, and the TIMI risk score, and remained an independent predictor of mortality after adjustment for clinical variables, troponin T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP).